Krauss et al., "Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin
induction," Transplantation, vol.
Lezaic, "Efficacy and safety of single and multiple dose antithymocyte globulin
induction treatment in living related renal transplantation," Biomedicine & Aging Pathology, vol.
Among these, 9120 (70.5%) received antithymocyte globulin
(ATG), 1687 (13.0%) received alemtuzumab, and 2137 (16.5%) received basiliximab for induction.
Pretransplant treatments included thyothepa (day -7; 8 mg/kg), fludarabine (days -6 to -3; 120 mg/[m.sup.2]), treosulfan (days -6 to -4; 42 g/[m.sup.2]), and antithymocyte globulin
(days -4 to -2; 45 mg/kg).
Cyclophosphamide and antithymocyte globulin
to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers.
The conditioning regimen used by Spitzer and colleagues included cyclophosphamide and thymic irradiation before transplantation, antithymocyte globulin
before and after transplantation, and cyclosporine.
Positive CDC-XM can be observed in other situations, notably in recipients with an autoimmune disease  or preexisting antibodies not detected by single-antigen bead array due to complement interference  or previously treated by desensitization protocols such as rituximab (RTX), antithymocyte globulin
, and intravenous immunoglobulins .
Patient Age/race/ Donor Induction Time to 1st PCR number sex/weight type/PRA 1st PCR (copies) (kg) (%) (days) 1 28/AA/M/95 D/16 ATG 178 42807 2 39/W/M/105 L/0 IL2-ra 90 1857 3 32/AA/M/116 D/0 ATG 85 741 4 32/AA/M/82 D/88 ATG 104 2987 Patient SCr/GFR/CrCl Dose-adjusted Peak PCR number at time of for CrCl at (copies) 1st PCR time of 1st PCR (mg/day) 1 2.2/43/53 900 42807 2 1.7/45/74 450 2257 3 1.8/53/67 450 6240 4 1.5/65/73 450 2987 ATG: antithymocyte globulin
; AA: African American; CrCl: creatinine clearance (mL/min); D: deceased donor; GFR: glomerular filtration rate (mL/min/[1.73.sup.2]); IL2-ra: interleukin 2 receptor antagonist; L: living donor; M: male; PCR: polymerase chain reaction; PRA: panel reactive antibodies; SCr: serum creatinine (mg/dL); W: White.
Moreover, immunosuppressive therapy with antithymocyte globulin
(ATG) and cyclosporine (CyA) is very effective for AA, while intensive immunosuppressive therapy with ATG and CyA might be a useful strategy for steroid-resistant HLH .
Induction therapy that used antithymocyte globulin
was administered for the first 3 days (Thymoglobuline, Genzyme Corporation, Naarden, the Netherlands).
Use of the immunosuppressant antithymocyte globulin
(ATG) increases the risk of cytomegalovirus (CMV) infection and disease during the early post-transplant period among cadaveric kidney recipients, according to Chinese researchers.
Patient characteristics n % Number of Patients 27 Number of Transplants 28 Median Age in years (range) 8 (2-17) Sex Male 17 60.7 Female 11 39.3 Risk Classification Class I 5 17.8 Class II 8 28.5 Class III 14 50 2nd transplant 3.5 Donor Status Thalassemia Minor 18 64.3 Normal 10 35.7 Stem Cell Source Bone Marrow 15 53.5 Peripheral Blood 10 35.7 Cord Blood 2 7.2 Cord Blood + Bone 1 3.6 Marrow (same donor) Conditioning Regimen Busulphan+ 11 39.3 Cyclophosphamide Busulphan+ 2 7.2 Cyclophosphamide+Thiotepa Pesaro Protocol 26 1 3.5 Pesaro Protocol 26+ATG 14 50 GVHD Prophylaxis Cyclosporine+Methotrexate 25 89.3 Cyclosporine 3 10.7 GVHD: Graft versus host disease; ATG: Antithymocyte globulin